Abstract:
On décrit de nouveaux vaccins agissant contre l'Actinobacillus pleuropneumoniae. Ils contiennent au moins une protéine de liaison à la transférine d'A. pleuropneumoniae et/ou une cytolysine d'A. pleuropneumoniae et/ou une APP4 d'A. pleuropneumoniae. On décrit aussi les séquences d'ADN codant pour ces protéines, les vecteurs comportant ces séquences et les cellules hôtes transformées par ces vecteurs. On peut utiliser ces vaccins pour traiter ou prévenir les infections respiratoires porcines.
Abstract:
Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.
Abstract:
The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S.iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.
Abstract:
The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.
Abstract:
Novel vaccines for use against Actinobacillus pleuropneumoniae are disclosed. The vaccines contain at least one A. pleuropneumoniae transferrin binding protein and/or one A. pleuropneumoniae cytolysin and/or one A. pleuropneumoniae APP4. Also disclosed are DNA sequences encoding these proteins, vectors including these sequences and host cells transformed with these vectors. The vaccines can be used to treat or prevent porcine respiratory infections.
Abstract:
The CAMP factor gen of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.
Abstract:
Novel Haemophilus somnus immunogenic proteins are disclosed. The proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections. The proteins are conveniently produced using recombinant technology.
Abstract:
Cloning and expression of genes encoding H. somnus transferring-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections, as well as in diagnostic methods for determining the presence of H. Somnus infections.
Abstract:
Novel vaccines for use against Actinobacillus pleuropneumoniae are disclosed. The vaccines contain at least one Actinobacillus pleuropneumoniae outer membrane lipoprotein A, or an immunogenic fragment thereof. Also disclosed are DNA sequences encoding these proteins, vectors including these sequences and host cells transformed with these vectors. The vaccines can be used to treat or prevent porcine respiratory infections.
Abstract:
Compositions and methods for stimulating an immune response against a secreted enterohemorragic Escherichia coli (EHEC) antigen are disclosed. The compositions comprise EHEC cell culture supernatants.